PHARMA MAR (PHM.MC) -- ehemals Zeltia (Seite 81)

[bonDiacomova]

J & J antrag auf zulassung durch FDA : frist bis entscheid 24. 10. 2015

Official Notices to the CNMV
http://www.zeltia.com/en/official-notices-to-the-cnmv

05.05.15 I+D: resultados obtenidos; licencias, patentes y marcas

FDA verlaengert die frist zur pruefung von YONDELIS®
gegen sarcoma de tejidos blandos um 3 monate ---> 24.10.2015

La FDA ha informado a Janssen, socio de Pharma Mar S.A. en Estados Unidos,
que el nuevo plazo para terminar la evaluación finaliza el 24 de octubre de 2015.

[bonDiacomova]

Antwort auf Beitrag Nr.: 49.183.670 von bonDiacomova am 26.02.15 14:52:45

2015 verkaeufe Q I

First Quarter 2015 Financial Results
http://www.zeltia.com/media/files/PR%201Q_2015(1).pdf


Q I 2014 - 19,7 mil
Q II 2014 - 18,3 mil
Q III 2014 - 19,4 mil
Q IIII 2014 - 19,4 mil

ges 2014 - 76,8 mil

Q I 2015 - 19,8 mil

---
die letzte rate des vertrages mit J&J aus 2011
in hoehe von 10 mil dollar ist geflossen

[bonDiacomova]

wallstreet online - deutsche PR von Newswire - gefunden bei pharma jonpi

PharmaMar wird auf dem AACR Annual Meeting 2015 Daten
zu den Krebsmittelkandidaten PM1183 und Plitidepsin präsentieren

http://www.wallstreet-online.de/nachricht/7537151-pharmamar-…

[bonDiacomova]

Antwort auf Beitrag Nr.: 49.471.613 von bonDiacomova am 01.04.15 09:18:10

short - auffaellige bewegungen

- stand 11.02.2015
11 416 357 stuecke

- stand 31.03.2015
13.562.654 stuecke

- stand 15.04.2015
14.171.059 stuecke

neu
2.503.653
geschl. intraday
398.589
geschl aelt.
1.718.711
net.neu
386.353

[bonDiacomova]

AACR Annual Meeting 2015 - in Philadelphia April 18-22

Combination of the anticancer drug PM1183
with PARP inhibitors and doxorubicin results in a synergistic effect
against breast cancer cell lines and a SCLC mouse tumor model, respectively.

The anticancer candidate plitidepsin binds to eEF1A2, a novel therapeutic
target in multiple myeloma, and shows activity in patient-derived tumor mouse
models from a wide range of solid tumors and hematological cancers.

The new antibody-drug conjugate (ADC), MI130004, shows in vivo potent and
long- lasting anticancer effects in breast tumors overexpressing HER2


"Our priority remains improving lives and treatment outcomes for patients with cancer.
We are committed to the discovery of new targets and innovative therapeutic options,"
says Carmen Cuevas, PhD, R&D Director at PharmaMar.
"The new data we are presenting onPM1183 demonstrate that
we are identifying new mechanisms of action."




ADC MI130004

A recent breakthrough of the Company is the development of a new ADC,
MI130004, which combines the HER2-targeting monoclonal antibody trastuzumab
with the marine-derived anticancer agent PM050489.

MI130004, a new antibody-drug conjugate, induces a strong, long-lasting
antitumor effect in HER2-expressing breast tumor models. (Abstract #2480).

Lead author Carmen Cuevas, PhD will be at the AACR to address the media

The data underscore the potent and long-lasting activity against HER-expressing breast tumors
in mice and the effect in survival. The positive results show great promise for this product.


http://www.prnewswire.com/news-releases/pharmamar-to-present…

[bonDiacomova]

short

- stand 11.02.2015 http://www.wallstreet-online.de/community/posting-drucken.ph…
11 416 357 stuecke

- stand 31.03.2015
13.562.654 stuecke

[bonDiacomova]

insider kaeufe

uebersicht : https://www.cnmv.es/Portal/Consultas/DerechosVoto/Participes…
aufs datum klicken :

andrade detrell 100 000 st am 17.03.
https://www.cnmv.es/Portal/verDoc.axd?t={1f565cbd-f87b-4603-…

fernández sousa 100 000 st am 17.03.
https://www.cnmv.es/Portal/verDoc.axd?t={ec5e159b-10ba-482c-…



Zeltia poised for significant potential growth, Edison raises valuation

Plans to restructure the group (through a reverse merger whereby
its PharmaMar division will absorb the parent company, Zeltia)
and seek an IPO in the US could be transformational in terms of strengthening
its financial and commercial abilities. Then there is the potential for the
oncology pipeline to provide upside as it enters a catalyst-rich period.

We raise our valuation to €1.03bn or €4.65 per share,
ahead of a number of key catalysts in 2015.

http://pharma-jonpi.blogspot.com.es/

Yondelis, already marketed in 80 countries,
could gain important new regulatory approvals in 2015
as a second-line treatment for STS (soft tissue sarcoma)
- in the US (PDUFA in July)
- and Japan (Q315).
This could significantly boost revenues through milestones
and royalties from its partners (Janssen in the US, Taiho in Japan).

PM01183 (a Yondelis follow-on) has generated highly encouraging clinical
data in ovarian cancer and SCLC and is poised for rapid development in 2015.
Data from a Phase III study with Aplidin in multiple myeloma are due in Q415.

[bonDiacomova]

IPO in the US

The Board of directors will also request
that Pharma Mar seek an IPO in the US

Madrid, 26 February 2015:

In connection with the information released on 2 December
2014, regarding the planned merger between Zeltia, S.A.
("Zeltia") and its wholly-owned subsidiary Pharma Mar, S.A. ("Pharma Mar")
and the subsequent intention to request that the resulting company
seek an IPO in the US, it is hereby disclosed that the Board of Directors
of Zeltia resolved today to propose to the Company's Shareholders' Meeting,
to be held in June, that a reverse merger take place, i.e.
that Zeltia be absorbed by PharmaMar.

one PharmaMar share for one Zeltia share,
after which a request would be submitted to list PharmaMar shares
on the same official markets where Zeltia shares are currently listed.

The Board of Directors' decision to execute a reverse merger as opposed
to direct merge is based on technical reasons.
In relation to the financial statements, the reverse merger has
no effect on the Group's consolidation scope.

Zeltia's next Board of Directors meeting, to be held in May,
is expected to draw up the merger proposal and call a Shareholders' Meeting ( vorraussichtlich juno )
to which the proposal will be submitted for approval.

http://www.firstwordpharma.com/node/1266056?tsid=1#axzz3T0v4…



- FDA us vorraussichtlich julei
- PMDA japon vorrauss. oktober
- fase III de Aplidin® vorr. 1 HJ

http://pharma-jonpi.blogspot.com.es/



27.02.2015 von Thomas Schönemann

Anwendungsbeobachtung zeigt bei Weichgewebssarkom vergleichbare
oder bessere Wirksamkeitsergebnisse als in klinischen Studien

Von den 304 Patienten, deren Erkrankung nach sechs Behandlungszyklen
als progressionsfrei eingestuft wurde, erhielten 227 weiterhin Trabectedin
und erreichten signifikant überlegene PFS- (11,7 gegenüber 7,6 Monaten)
und OS-Zeiträume (24,9 gegenüber 16,9 Monate) im Vergleich zu jenen,
die die Behandlung beendeten.

http://www.krebs-nachrichten.de/pharma-details/yondelisr-anw…

[bonDiacomova]

Antwort auf Beitrag Nr.: 48.169.219 von bonDiacomova am 30.10.14 08:55:46

zahlen 2014

siehe HP

...en oncología las ventas netas de Yondelis®
han ascendido a 76,8 millones de euros


entwicklung netto verkaeufe yondelis :

Q I 2009 - 8,3 mil
Q II 2009 - 11,1 mil
Q III 2009 - 11,0 mil
Q IIII 2009 - 13,4 mil

ges 2009 - 43,8 mil

Q I 2010 - 16,6 mil
Q II 2010 - 17,0 mil
Q III 2010 - 18,2 mil
Q IIII 2010 - 20,5 mil

ges 2010 - 72,3 mil

Q I 2011 - 19,6 mil
Q II 2011 - 18,6 mil
Q III 2011 - 18,4 mil
Q IIII 2011 - 17,5 mil

ges 2011 - 74,1 mil

Q I 2012 - 16,4 mil
Q II 2012 - 16,2 mil
Q III 2012 - 17,0 mil
Q IIII 2012 - 16,6 mil

ges 2012 - 66,2 mil

Q I 2013 - 16,7 mil
Q II 2013 - 18,5 mil
Q III 2013 - 18,1 mil
Q IIII 2013 - 19,6 mil

ges 2013 - 72,9 mil

Q I 2014 - 19,7 mil
Q II 2014 - 18,3 mil
Q III 2014 - 19,4 mil
Q IIII 2014 - 19,4 mil

ges 2014 - 76,8 mil

[bonDiacomova]

markteilnehmer

ist aber auch schwerer einzuschaetzen

1. weil mehr stuecke pro tag gehandelt werden
"frueher" waren es so 400 000 durschschnittlich dann 600 000
der tagesdurschnitt der letzten 3 monde : 1.072.180
quelle : https://es.finance.yahoo.com/q?s=ZEL.MC


2. "der shortie"

shorts stand freitag 06.02. :

neu am freitag : 213991 st
intraday gedeckt : 16142 st
aeltere gedeckt : 12566 st

z.z. short : 9 994 505 st



shorts gestern - stand 11.02.

neu am mittwoch : 1 094 090 st
intraday gedeckt : 2 600 st
aeltere gedeckt : 143 749 st

z.z. short : 11 416 357 st



neues model einer schweizer uhr